DOSING AND USE OF LONG-ACTING CLR/RAMP AGONISTS

摘要

Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo. The agonists are delivered to an individual at a dose sufficient to reduce hypertension and ischemic injury, and to reduce cardiotoxicity associated with chemotherapeutic agents.